BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 26, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Ovarian cancer illustration
Cancer

Kancera advances KAND-567 toward clinic for ovarian cancer

Sep. 23, 2022
Kancera AB has shown that its Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer.
Read More
Light micrograph and 3D illustration of adipose tissue.
Biomarkers

miR-24-3p correlates with adipose tissue functionality in type 2 diabetes and obesity

Sep. 23, 2022
Impairment in the functionality of the adipose tissue is crucial for obesity-related metabolic comorbidities and may trigger the onset of type 2 diabetes. The adipose tissue has been proposed as a main contributor of circulating miRNAs (miRNAs), but has not yet been characterized for these markers.
Read More
Diabetes glucose monitor
Biomarkers

BCL2L1 alternative splicing behind severity of diabetic nephropathy

Sep. 23, 2022
Understanding how alternative splicing is regulated and how it contributes to disease pathogenesis might open new therapeutic options for the treatment of diabetic nephropathy (DN). Bcl-2-like protein 1 (BCL2L1), also known as BCLX, for which two alternative splicing forms (Bcl-xL and Bcl-xS) have been seen to have antagonistic effects.
Read More
Cancer

Targeting GSN/CLEC9A axis may be a therapeutic option for cancer treatment

Sep. 23, 2022
C-type lectin domain containing 9A (CLEC9A) is a receptor for dendritic cells (DCs) that binds...
Read More
Mouse's fat cells, blood vessels.
Endocrine/Metabolic

Integrin α5β1 inhibitor CLT-28643 improves cardiac function in obese mice

Sep. 23, 2022
Recently, extracellular matrix remodeling has emerged as a key element involved in the...
Read More
Cancer

IRBM reports discovery of novel SHP2 allosteric inhibitors with improved preclinical profile

Sep. 23, 2022
Researchers from IRBM Science Park have discovered novel tyrosine-protein...
Read More
Electron micrograph of red blood cell infected with Plasmodium falciparum surrounded by knobless uninfected blood cells.
Infection

New classes of Plasmodium falciparum IspD could yield effective nanomolar antimalarials

Sep. 23, 2022
The 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, a metabolic pathway for the...
Read More
Colorized scanning electron micrograph of M. tuberculosis bacteria.
Infection

GSK and Bioversys advance ethionamide boosters for treating tuberculosis

Sep. 23, 2022
GSK plc and Bioversys AG have described the development of ethionamide boosters...
Read More
Neurology/Psychiatric

Microprotein has big effect on AD risk

Sep. 23, 2022
By Anette Breindl
Variants in a newly discovered microprotein affected the risk of Alzheimer’s disease more than any other known risk variant besides ApoE. The protein, dubbed SHMOOSE by its discoverers, was identified in a mitochondrial-wide association study (miWAS). The researchers reported their findings in the Sept. 21, 2022, issue of Molecular Psychiatry. The newly identified variant is not rare – it occurs in about a quarter of the Caucasian population, slightly more than the ApoE4 allele. Its effects are also not subtle – in their paper, the team estimated that those with the high-risk variant SHMOOSED47N were roughly 30% more likely to develop AD than those without.
Read More
Illustration of morphological types of pyramidal cells within the rodent cortical layer.
Neurology/Psychiatric

Early postnatal treatment can delay late-onset neurodegeneration

Sep. 23, 2022
By Nuala Moran
The mutant gene causing Huntington’s disease (HD) is active from the earliest stages of brain development, even though the pathology is not evident until between 30 and 50 years of age. That delay is ascribed to plasticity enabling the brain to compensate to such an extent that overt signs of disease take time to develop. As a result, it is difficult to plot a route from early molecular defects to development of HD several decades later.
Read More
Previous 1 2 … 1256 1257 1258 1259 1260 1261 1262 1263 1264 … 17998 17999 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing